Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05176392

Combined Transcranial Magnetic Stimulation and Therapy for MTBI Related Headaches

This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

VA San Diego Healthcare System

San Diego, California, 92161, United States

Location status: Recruiting

Location contact

Albert Y Leung, MD

CONTACT

Caleb Lopez, BS

CONTACT

[email protected]

858-552-8585 ext. 2638

About this study

This study will be enrolling a total of 240 veterans or active military over a 4 year period at the VA San Diego Healthcare System (VASDHS). Participants will be randomized into one of four groups:

Group A: active rTMS with telehealth headache management therapy Group B: active rTMS with telehealth headache education control Group C: sham rTMS with telehealth headache management therapy Group D: sham rTMS with telehealth headache education control

Individual participation will consist of 19 visits to the VASDHS and 11 telehealth sessions over the course of 6-7 months. The in person visits will be divided into the following phases:

  • PRE-TREATMENT ASSESSMENTS PHASE (weeks 1-2) which consists of Visit 1 (Screening Visit) and Visit 2 (Baseline Assessments with MRI scan);
  • INDUCTION TREATMENT PHASE (weeks 3-4) consists of Visits 3-12 (10 weekday neuronavigation guided rTMS sessions at >24 and <72 hours apart); and
  • POST-TREATMENT ASSESSMENTS AND MAINTENANCE TREATMENT PHASE (weeks 5-24) consists of 4 initial biweekly post-induction treatment assessments and maintenance treatments (Visits 13-16)) and two additional monthly post-induction assessments and maintenance treatments (Visits 17-18) and one final study visit (Visit 19).

Eight weekly telehealth therapy/education sessions will be conducted from week 3 to 10 with additional three bolster sessions at 4 weeks apart. During the baseline and follow up visits, assessments will be conducted to evaluate headaches, neurobehavioral symptoms, depressive symptoms, post-concussion symptoms, and quality of life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mild Traumatic Brain Injury (mTBI)
  • Chronic headaches > 3 months after injury
  • Aged 18-65
  • No prior TMS treatment
  • Persistent Headaches with an intensity > 30 / 100
  • No history of daily headache prior to mTBI

Exclusion criteria

  • Pregnant
  • Pacemaker or any metal in body that would prevent MRI
  • History of dementia or major psychiatric disease, such as bipolar disorder or schizophrenia
  • Presence of any other chronic neuropathic pain states
  • History of seizure
  • Pending litigation
  • Can't understand English
  • History of chronic headache like migraine prior to mTBI
  • Evidence in chart of exacerbation of depressive/anxiety symptoms, active substance dependence, suicidal intent or attempt within previous month

Treatment and study plan

Active rTMS

Device

Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.

Headache Management Therapy

Behavioral

Therapy will be provided on headache management.

sham rTMS

Device

Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.

Headache Education Control

Behavioral

In the control, educational sessions on headaches will be provided.

Primary outcomes

  1. Intensity of Persistent Headaches

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the intensity of persistent headaches, from a scale of 0, being no pain, to 10, being worst possible pain.

  2. Intensity of Debilitating Headaches

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the intensity of debilitating headaches, from a scale of 0, being no pain, to 10, being worst possible pain.

  3. Persistent Headache Frequency

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the frequency per week of persistent headaches

  4. Debilitating Headache Frequency

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the frequency per week of debilitating headaches

  5. Debilitating Headache Interference

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the interference of debilitating headaches for activities of daily living, from 0, being no interference, to 10, being worst possible interference.

Secondary outcomes

  1. Headache Impact Test

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Measures the impact of headache on an individual's ability to function at work, school, home, and/or social situations. Each item is measured from never, rarely, sometimes, very often, or always, with scores of 6, 8, 10, 11, and 13 respectively. A higher score correlates to a greater negative impact of headaches on quality of life.

  2. Neurobehavioral Symptom Inventory

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses the severity of symptoms in the following areas: somatic, cognitive, affective, and sensory. Each item ranges from 0-4 with a higher score indicating a worse outcome.

  3. Hamilton Rating Scale for Depression

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Rates the severity of symptoms observed in depression such as low mood, insomnia, agitation, anxiety and weight loss. Scores range from 0 to 53, with a higher score indicating a larger degree of depression.

  4. Rivermead Post-Concussion Symptoms Questionnaire

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses somatic, cognitive, and emotional symptoms experiences after traumatic brain injury. Each item ranges from 0-4, with a higher score indicating a worse outcome.

  5. Short Form Health Survey-36

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Measures health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health. Each item is scored on a 0 to 100 range, with a higher score indicating a worse outcome.

  6. Short-Form NEURO-QoL

    Time frame: Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

    Assesses quality of life related to neurological disorders. Each item ranges from 1-5, with a higher score indicating a worse outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Caleb Lopez, BS

CONTACT

[email protected]

858-552-8585 ext. 2638

Sponsors and collaborators

Lead sponsor

Veterans Medical Research Foundation

Other

Registry information

Official study title

Combined Nonpharmacological Therapies for MTBI-Related Headaches

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jan 4, 2022
Registry last updated
Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.